Vivani (VANI) Insider Buys: Williams Increases Holdings to 20.7M Shares
Rhea-AI Filing Summary
Gregg Williams, a director and reported 10% owner of Vivani Medical, Inc. (VANI), purchased shares in two private transactions during 2025. On 03/26/2025 he bought 1,473,215 shares at $1.12 per share (gross $1,650,000.80). On 08/11/2025 he bought 595,238 shares at $1.26 per share (gross $749,999.88). Following the reported transactions dated 09/15/2025, the filing shows beneficial ownership totaling 20,708,548 shares, with a detailed breakdown across trusts and entities for which he has voting and dispositive power. The Form 4 was signed by an attorney-in-fact on 09/17/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Director purchased additional common shares totaling about $2.40 million in two private purchases, increasing reported beneficial holdings to 20.7 million shares.
The reporting shows two private purchase transactions disclosed by Share Purchase Agreements: 1,473,215 shares at $1.12 and 595,238 shares at $1.26, with gross proceeds reported as $1,650,000.80 and $749,999.88 respectively. These purchases are documented as private-sale transactions and are reflected in the reporting person's aggregated beneficial ownership of 20,708,548 shares across direct holdings and several trusts and entities for which he has voting and dispositive power. For investors and analysts, the filing provides clear transaction sizes and prices but does not include market timing rationale or any option/derivative activity.
TL;DR: An insider who is both a director and >10% owner increased shareholdings via private purchases; ownership structure is concentrated across trusts and entities.
The Form 4 discloses that Gregg Williams holds voting and dispositive power over a concentrated block of shares including direct ownership and multiple trusts/entities totaling 20,708,548 shares. The filing clearly identifies the nature of the transactions as private sales pursuant to Share Purchase Agreements dated 03/26/2025 and 08/11/2025 and documents signature via attorney-in-fact. The disclosure is specific about quantities and prices but does not provide any governance actions or changes to board responsibilities.